Amylyx Pharmaceuticals (AMLX) Interest Expenses (2021 - 2026)

Amylyx Pharmaceuticals' Interest Expenses history runs 6 years deep, the most recent figure standing at $49.7 million for Q1 2026.

• On a quarterly basis, Interest Expenses rose 1517.59% year-over-year to $49.7 million in Q1 2026; TTM through Mar 2026 was $49.7 million, a 1517.59% increase from a year earlier, with the FY2025 full-year figure at $199.6 million, up 25.89% from the prior year.
• Interest Expenses improved to $49.7 million in Q1 2026 per AMLX's latest filing, from $43.0 million in the prior quarter.
• Across five years, Interest Expenses topped out at $158.5 million in Q4 2024 and bottomed at $287000.0 in Q2 2024.
• The 5-year median for Interest Expenses is $43.0 million (2025), against an average of $47.4 million.
• Biggest YoY gain for Interest Expenses was 26323.67% in 2024; the steepest drop was 99.57% in 2024.
• Year by year, Interest Expenses stood at $600000.0 in 2022, then changed by 0.0% to $600000.0 in 2023, then surged by 26323.67% to $158.5 million in 2024, then tumbled by 72.9% to $43.0 million in 2025, then gained by 15.77% to $49.7 million in 2026.
• Per Business Quant, the three latest AMLX Interest Expenses figures stand at $49.7 million (Q1 2026), $43.0 million (Q4 2025), and $52.6 million (Q3 2025).